A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumor. Such a biopsy can detect lingering disease and could serve as a guide for deciding whether a patient should undergo further treatments due to some…
Prostate cancer is one of the most common cancers among men. Patients are determined to have prostate cancer primarily based on PSA, a cancer factor in blood. However, as diagnostic accuracy is as low as 30%, a considerable number of patients undergo additional invasive biopsy and thus suffer from resultant side effects, such as bleeding and pain.
A new advanced computing technique using routine medical scans to enable doctors to take fewer, more accurate tumour biopsies, has been developed by cancer researchers at the University of Cambridge. This is an important step towards precision tissue sampling for cancer patients to help select the best treatment. In future the technique could even replace clinical biopsies with ‘virtual…
Hologic, Inc. has completed the acquisition of Somatex Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, for approximately $64 million. The company was previously owned by E-Med Solutions GmbH, Berlin, a group of investors led by German private equity company Westlake Partners.
Researchers have developed a novel three-dimensional imaging system to diagnose cervical cancer faster, non-invasively and more efficiently than conventional methods.
A new study sheds light on proteins in particles called extracellular vesicles, which are released by tumor cells into the bloodstream and promote the spread of cancer. The findings suggest how a blood test involving these vesicles might be used to diagnose cancer in the future, avoiding the need for invasive surgical biopsies.
The Norfolk and Norwich University Hospital (NNUH) has taken the first steps towards establishing a digital histopathology service, which will help to improve cancer care. New systems are being introduced to embrace new technology to track specimens, digitise slides and enable clinicians to analyse and report cases digitally on computers.
Tissue biopsy slides stained using hematoxylin and eosin (H&E) dyes are a cornerstone of histopathology, especially for pathologists needing to diagnose and determine the stage of cancers. A research team led by MIT scientists at the Media Lab, in collaboration with clinicians at Stanford University School of Medicine and Harvard Medical School, now shows that digital scans of these biopsy…
Biopsies are standard procedures in interventional radiology, not least for patients with a suspected tumor. In this instance, MRI is increasingly the method of choice for guiding minimally invasive tissue sampling. Yet this involves having to undergo repeated MRI scans, which patients find uncomfortable. In an ongoing R&D project, Fraunhofer researchers have now developed a system that…
A team of researchers has developed a novel technology that could sensitively and accurately detect and classify cancer cells, as well as determine the disease aggressiveness from the least invasive biopsies. With this new technology called STAMP (Sequence-Topology Assembly for Multiplexed Profiling), comprehensive disease information can be obtained faster, at a much earlier stage of the…
Using MRI scans to target biopsies is more effective at detecting prostate cancers that are likely to need treatment than standard ultrasound guided biopsies alone, according to research published in JAMA Network Open. The research, led by the National Institute for Health Research (NIHR) and Universities of Bristol, Ottawa, Exeter and Oxford, combined the results from seven studies covering…
Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy.
It is non-invasive, delivers a chance of early diagnosis, prognostic information and sequential monitoring, and, believes Professor Francesco Salvatore, the enormous potential of liquid biopsies has still to be reached. However, the positive results obtained so far have ‘opened the door to a promising new multi-faceted group of tumour markers, at present collectively designated “liquid…
Often referred to as the ‘Achilles’ heel’ of histopathology, the sample entry has posed considerable challenges in pre-analytics for several decades. We visited the Munich-based lab automation start-up Inveox GmbH. Time-intense, highly manual processes in labs are expensive, error-prone and the most common reason for irregularities in cancer diagnoses. In Germany alone, every year hundreds…
New research indicates that many kidneys obtained for transplantation from deceased donors are not being used because of biopsy findings despite their unreliability and reproducibility. The findings, which appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN) and will be published at ASN Kidney Week 2018, may suggest an urgent need to re-examine the…
Liquid biopsies can increasingly help diagnose and monitor breast cancer, and tracking circulating tumour cells (CTC) in metastatic patients could prove effective in these applications and treatment planning. Efforts are currently underway to demonstrate CTC clinical use and much can be learned from completed studies in prostate cancer, speaker Michail Ignatiadis MD PhD highlighted in a dedicated…
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test. Hong Chen, a biomedical engineer, and Eric C. Leuthardt, MD, a neurosurgeon, led a team of engineers, physicians and researchers who have developed a…
A new imaging technology to grade tumour biopsies has been developed by a team of scientists led by the Department of Physics and the Department of Surgery and Cancer at Imperial College London. Publishing their results in the journal Convergent Science Physical Oncology, they describe how their new method promises to significantly reduce the subjectivity and variability in grading the severity…
Recognising malignant tissue remains a tricky task. While today, most patients undergo a biopsy, an invasive procedure where tissue is sampled, stained and assessed, researchers are exploring the potential of optical biopsy, the visual assessment of suspect tissue. The interest in optical biopsy ‘is indeed enormous,’ confirms Dr Thomas Bocklitz, physicist at Friedrich-Schiller University in…
Two new systems developed by Hologic Inc. recently received the European CE Mark: The MyoSure Manual and the Brevera Breast Biopsy System with CorLumina Imaging Technology.
Enhancing the diagnosis of breast cancer is the stated goal of a research team at the German Cancer Research Center (DKFZ) in Heidelberg. The scientists have combined an advanced method of diffusion-weighted MR imaging with intelligent image analysis methods to detect malignant changes in tissues. This method may help avoid many control biopsies following suspicious findings from mammography…
Hologic, Inc. announced it has obtained a CE Mark in Europe for the Brevera breast biopsy system with CorLumina imaging technology, a groundbreaking real-time breast biopsy and verification system that improves the patient experience and streamlines the biopsy process from start to finish. The first-of-its-kind Brevera system is designed to increase biopsy accuracy with real-time imaging that…
Cancer surgeons perform an estimated 1.7 breast biopsies each year, according to the American Association of Preferred Provider Organizations. This makes the procedure a significant proportion of cases referred to anatomic pathologists. This surgery, however, is time-consuming and not always accurate due to shortcomings in existing surgical technology and to human error. Now, a 3D-printed…
Lars Schimmöller MD, associate professor of radiology at Düsseldorf University Hospital, tackled current diagnosis of prostate cancer (PCa) and addressed tumour detection, staging, active surveillance and recurrence during the Medica Academy session on Imaging Update. He also highlighted how MRI helps improve biopsies and avoid unnecessary surgery in PCa.
Agena Bioscience, a global provider of molecular genetic solutions, announced it has been selected to participate as an innovative technology provider in the ‘Liquid biopsies and IMAging for improved cancer care’ (LIMA) project. The LIMA project has been awarded a EUR 6.3 million Horizon 2020 European Union research grant to develop an integrated approach for personalized cancer treatment.…